v3.26.1
Segment Information (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Segment Reporting Information [Line Items]      
Operating expenses $ 6,817 $ 6,557  
Segment net loss 6,780 6,302  
Total Assets 42,353   $ 39,393
Biopharm Division [Member]      
Segment Reporting Information [Line Items]      
Operating expenses 6,000    
Segment net loss 6,012 5,645  
Total Assets 41,900    
Neuromodulation Division [Member]      
Segment Reporting Information [Line Items]      
Operating expenses 800    
Segment net loss 768 $ 657  
Total Assets $ 500